Home
 /
Papers
 /
Molecular Biology
 /
A distal promoter and aberrant splicing enable canonical translation of out-of-frame proteins in Huntington’s disease
Preprint
Open access
V1
Top 1% · Validated by QED

A distal promoter and aberrant splicing enable canonical translation of out-of-frame proteins in Huntington’s disease

Rachel Anderson, Tanishk Soni, Ankur Jain
October 2025
 ·
bioRxiv
 ·
DOI 
10.1101/2025.10.20.683480
94
%
Reproducible
QED Impressions
This paper passed independent validation.
QED's automated review checked the evidence supporting each claim, the statistical methods, and whether the results are reproducible from the data provided.

It ranks in the top 1% of preprints assessed in Molecular Biology this quarter.
Run full QED analysis
Read paper
Save

Why this is interesting

By demonstrating that out-of-frame HTT proteins arise via AUG-initiated, splicing-mediated translation from a primate-specific upstream promoter, this work overturns the RAN translation paradigm, explains rodent model failures, and identifies splice junctions as therapeutic targets.

QED claims analysis

Summary

A primate-specific promoter located 33 kb upstream of the HTT gene generates extendedHTT transcripts that undergo repeat-length-dependent aberrant splicing into HTT exon 1, creating AUG-initiated open reading frames that enable canonical translation of polyalanine and polyserine proteins in Huntington's disease through a splicing-mediated mechanism rather than non-AUG (RAN) translation.

See full analysis
Main Claim 1 –

Unannotated HTT promoter resides ~33 kb upstream

Supporting evidence

  • CAG RNA affinity capture enriches full-length repeat transcripts
Main Claim 2 –

Expanded CAG repeats drive repeat-length-dependent extendedHTT-to-exon1 splicing

Supporting evidence

  • Primate-specific extendedHTT promoter region missing from HD animal models
Main Claim 3 –

extendedHTT–exon1 splicing creates AUG ORFs for polyAla/polySer translation

Supporting evidence

  • extendedHTT is expressed in human brain and encodes polyAla/polySer
  • extendedHTT transcripts may evade NMD via translation and polyadenylation

Abstract

Expanded CAG trinucleotide repeats cause more than a dozen neurodegenerative diseases, including Huntington’s disease (HD). In several disorders, these repeats are translated in multiple reading frames without identifiable AUG start codons. This process, called repeat-associated non-AUG (RAN) translation, generates aggregation-prone proteins, but its molecular basis remains unclear. Here, using affinity capture of CAG-repeat-containing RNAs, we identify a previously unannotated promoter ~33 kb upstream of the HTT gene. Transcripts initiating from this promoter undergo repeat-length-dependent aberrant splicing into exon 1 of the canonical HTT, embedding the CAG repeat in AUG-initiated frames encoding polyalanine and polyserine proteins. Comparative genomics indicates that this upstream promoter is primate-specific, helping explain inconsistencies across rodent models. Our findings establish a direct, AUG-dependent, splicing-mediated mechanism for out-of-frame repeat proteins in HD, expose critical gaps in current animal models, and identify novel splice junctions as potential therapeutic targets.

Related papers

How the QED Score works

QED Score is a validated AI-based quality metric that evaluates life science papers on two dimensions: originality and validity. Each manuscript is anonymized, broken down into its claims and supporting evidence, and examined by specialized AI agents for statistical rigor, consistency across figures, and fit with the existing literature. Scores are percentile ranks, so they're comparable across fields. In blinded tests, expert professors sided with QED Score over journal rank in 75% of decisive cases.
Read the methodology

Free access for academic researchers

Create your free QED account to validate your research, strengthen grant proposals, and uncover scientific insights.
We've sent you an access link.
Please check your inbox.

Didn't get your email? Check your spam folder or reach out to info@qedscience.com

Oops! Something went wrong while submitting the form.
Looking for QED for pharma, biotech or life science organizations?